Positive Data From Nektar Therapeutics

Hapoalim Securities has published a research report on Nektar Therapeutics NKTR after the company announced positive news from the full Phase 2 trial of NKTR-102. In the report, Hapoalim writes "Nektar announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer and the results were more impressive than the preliminary results presented in June. In June, Nektar announced confirmed and unconfirmed RECIST responses of 21% (14/66) overall for single-agent NKTR-102, with 18% (6/33) for the q14d dose regimen and 24% (8/33) for the q21d dose regimen. Confirmed ORR for all evaluable patients in this latest reporting of data was 32% (10/31) for the q14d schedule and 26% (9/35) for the q21d schedule, including two confirmed complete responses (CRs) on the q14d schedule and an additional four patients had near CRs." Hapoalim Securities reiterates its Buy rating and $19 price target. Nektar Therapeutics closed yesterday at $14.06.